Evidence map›Paper›PMID 36337024›Full record

ArticleProblemy endokrinologii2022

[Testosterone and Alzheimer's disease].

K O Kuznetsov, R R Khaidarova, R H Khabibullina, E S Stytsenko, V I Filosofova, I R Nuriakhmetova, E M Hisameeva, G S Vazhorov, F R Khaibullin, E A Ivanova and 1 more

Open access · diamondAbstract readEnglish Abstract
In one paragraph

Article in Problemy endokrinologii, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

K O KuznetsovN.I. Pirogov Russian national research medical university.
R R KhaidarovaBashkir state medical university.
R H KhabibullinaFirst Pavlov state medical university of St. Petersburg.
E S StytsenkoSaint Petersburg state pediatric medical university.
V I FilosofovaFirst Pavlov state medical university of St. Petersburg.
I R NuriakhmetovaBashkir state medical university.
E M HisameevaBashkir state medical university.
G S VazhorovI.N. Ulyanov Chuvash State University.
F R KhaibullinBashkir state medical university.
E A IvanovaKursk State Medical University.
K V GorbatovaKursk State Medical University.
Bashkir State Medical University · RUFirst Pavlov State Medical University of St. Petersburg · RUKursk State Medical University · RUChuvash State University · RUPirogov Russian National Research Medical University · RUSaint Petersburg State Pediatric Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that causes dementia in half of the cases. Asthma is usually found in people over 65 years of age. The etiopathogenesis of the disease is multifactorial and includes genetic factors, nutritional disorders, mitochondrial dysfunction, oxidative stress, and aging. Sex hormones have an important influence on the development of AD, as evidenced by a higher incidence in women than in men. Considering the significant influence of T on the maintenance of normal brain function, the present study is aimed at evaluating the impact of androgen deprivation therapy (ADT), as well as testosterone therapy, on the risk of AD development and progression. Although there is some clinical inconsistency between studies, androgens have a significant effect on brain function and are beneficial for AD patients. Low levels of circulating androgens should be considered as a significant risk factor for the development of AD and memory loss. With a reduced level of T in the plasma of men, its administration improves cognitive performance and memory, treatment should be started at an early stage of the disease. In men and women with AD, androgens improve mental state and slow the progression of the disease, providing a protective effect. In the future, it is necessary to conduct studies on a large population, taking into account personality factors and a more specific approach to assessing cognitive functions and the causal relationship of T administration in AD.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesProstatic NeoplasmsAndrogen AntagonistsAndrogensHumansMaleTestosteroneAndrogen AntagonistsAndrogensTestosterone

Identifiers

PMID36337024
PMCPMC9762454
OpenAlexW4308549114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.